Illustration Lung Cancer

LUNG CANCER

Lung cancer has the most established targeted therapy treatment landscape. Targeting specific genetic mutations, such as EGFR and BRAF mutations, ALK, ROS1 and NTRK gene rearrangements with drugs provides specificity towards cancer cells while sparing toxicity to normal cells and ultimately improving patient outcomes. Therefore, genetic testing is a crucial step in matching a patient to the right targeted therapy.

Our lung cancer-specific panels can meet all of your clinical needs for lung cancer patients at all disease stages. Optional PD-L1 immunohistochemistry (IHC) test is available to better guide immunotherapy decisions.

TETRADECAN®

Targets 14 key genes in lung cancer

Coverage of all exons and fusion-related introns in these genes to guide targeted therapy

  • 8 genes recommended by the National Comprehensive Cancer Network (NCCN) Guideline for lung cancer treatment: EGFR, ALK, MET, KRAS, ERBB2 (HER2), ROS1, RET, BRAF
  • 6 core genes in key signaling pathways associated with the efficacy of targeted therapy: NRAS, NF1, MAP2K1(MEK1), AKT1, PIK3CA, PTEN
WHO IS IT FOR

Newly diagnosed systemic treatment-naive lung cancer patients seeking targeted therapy

SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and others)

Product Tetradecan
Product Pulmocan

PULMOCAN®

Targets 139 key genes in lung cancer

  • Guides targeted therapy
  • Evaluates efficacy and toxicity of chemotherapies
  • Identifies potential drug resistance mechanisms
  • Reveals tumor genomic evolution during treatment
WHO IS IT FOR
  • Lung cancer patients at different stages of disease seeking precision medicine
  • Lung cancer patients progressed on targeted therapy or systemic treatment
  • Lung cancer patients with recurrent disease after surgery
SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and others)

VANGUARD™

DEPTH Now MATTERS

  • Minimally invasive approach: only 8-10mL of peripheral blood needed to test 139 key genes in lung cancer
  • ATG-seq technology combines 30,000x deep-sequencing and state-of-art background noise reduction technology to achieve ultra-high detection sensitivity and specificity in liquid biopsy
WHO IS IT FOR

Applicable to entire course of disease in lung cancer (Vanguard™ Dynamic Monitoring )

SAMPLE TYPES
Icon Liquid Biopsy

Liquid biopsy (plasma)

Product Vanguard

LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.

Learn more about our products and services or contact us today to discuss how we can partner together.

Contact Us